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Background: Obesity is associated with increased risk for stroke. The breath-holding index (BHI) is a measure of
vasomotor reactivity of the brain which can be measured with the transcranial Doppler (TCD). We aim to evaluate
obesity as an independent factor for altered cerebrovascular reactivity.
Methods: Cerebrovascular hemodynamics (mean flow velocities MFV, pulsatility index, PI, resistance index, RI, and BHI)
was determined in 85 non-obese (Body Mass Index, BMI ≤27 kg/m2) and 85 obese subjects (BMI ≥35 kg/m2) without
diabetes mellitus and hypertension. Anthropometric and metabolic variables, and scores to detect risk for obstructive
sleep apnea (OSA) were analyzed for their association with the cerebrovascular reactivity.
Results: The BHI was significantly lower in subjects with obesity according to BMI and in subjects with abdominal
obesity, but the PI and RI were not different between groups. There was a linear association between the BMI, the
HOMA-IR, the Matsuda index, the waist circumference, and the neck circumference, with the cerebrovascular reactivity.
After adjusting for insulin resistance, neck circumference, and abdominal circumference, obesity according to BMI was
negatively correlated with the cerebrovascular reactivity.
Conclusions: We found a diminished vasomotor reactivity in individuals with obesity which was not explained by the
presence of insulin resistance.
Keywords: Cerebrovascular, Insulin resistance, Obesity, Abdominal obesity, Transcranial dopplerBackground
Obesity is a condition which increases the risk of devel-
oping several diseases as a consequence of metabolic
derangements and by its mechanical effects [1]. The
promotion of insulin resistance and type 2 diabetes
confers increased cardiovascular risk in obese subjects
[2], which commonly coexist with hypertension and
dyslipidemia contributing further to the development
of vascular dysfunction and atherothrombotic process
[3], Within the atherothrombotic events, cerebrovascular
disease is one of the leading diseases for global disease
burden [4] and a cause of enormous rates of disability [5].
Data from epidemiological studies has shown hyperten-
sion, dyslipidemia, obesity, smoking, and diabetes mellitus* Correspondence: chelorf76@yahoo.com
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article, unless otherwise stated.to be risk factors for the development of cerebrovascular
disease [6].
Among the effects that obesity can have on the cardio-
vascular system, Obstructive sleep apnea (OSA) is com-
monly present as weight increases, being reported in
over 90% of people with severe obesity [7]; it is associ-
ated with sleep fragmentation, somnolence and hypox-
emia [8]. Several studies have found an increased risk of
developing cerebrovascular disease and myocardial in-
farction in people with OSA [9,10], as well as an associ-
ation between persistent hypoxia with inflammation and
altered production of adipokines [11].
In order to establish risk of having OSA, the combin-
ation of the Epworth somnolence scale (ESS), the sleep
apnea clinical scale (SACS) and night oximetry are sig-
nificantly correlated with polysomnography [12].
It is important to highlight that the reflection of obes-
ity over health can be very variable, according with thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tors, or metabolically healthy [13]. It was reported that
body mass index (BMI), abdominal circumference and
waist-to-hip ratio did not show to contribute to the pre-
diction of cardiovascular disease better than classical risk
factors by a study which calculated hazard ratios from 58
cohorts including individual records of 221,934 people in
17 countries [14]. In contrast, in the assessment of 92
patients (90% of them older than 50 years of age) with is-
chemic stroke, Singh et al. found BMI to be positively as-
sociated with carotid intima-media-thickness [15].
The transcranial Doppler (TCD) allows the non-
invasive evaluation of several physiological parameters of
the blood flow velocities (BFV) on the main basal intra-
cranial arteries. Its main clinical applications are related
with established cerebrovascular disease, malformations,
and monitoring during vascular procedures [16]. It pro-
vides information on the systolic, diastolic and mean
BFV (SBF, DBF, MBF). Measures related with the cere-
brovascular resistance are the Goslin’s Pulsatility Index
(PI), which is a measure of the variability of BFV in a
blood vessel, and the Resistance Index (RI), or Pourcelot
Index, which reflects the resistance against the arterial
flow originated in the distal microvascular vessels. A
retrospective study which performed TCD study in 1208
patients without cerebrovascular disease found that
the main factors associated with intracerebral athero-
sclerosis were age >65 years, smoking, hypertension,
and diabetes [17].
The cerebral BFV can also be modified by processes
which provoke vasoconstriction or vasodilation, allowing
for the evaluation of the cerebrovascular reactivity in re-
sponse to the injection of acetazolamide, hyperventilation,
or breath-holding [18]. Hypercapnia is an important
stimulus for cerebral vasodilation, and this condition has
allowed the development of a non-invasive test, known as
the apnea test, to establish the status of the cerebrovascu-
lar reactivity in different clinical conditions [19].
Several studies have utilized the cerebrovascular re-
activity to 1) assess the intracranial hemodynamic status
in patients with carotid artery disease to predict for the
development of cerebrovascular disease; 2) compare the
intracranial hemodynamics before and after endarterec-
tomy; 3) compare self-regulation and collateral flow in
different regions of the Willis circle; and to 4) predict
the development of dementia in patients with cerebro-
vascular disease [20,21]. One study found a cutoff value
of 0.69 to distinguish between normal and abnormal
cerebrovascular reactivity in subjects with carotid sten-
osis [22].
A diminished cerebrovascular reactivity indicates that
the reserve self-regulation in the brain is reduced, which
has been observed in subjects with diabetes and hyperten-
sion [23]. In relation with metabolic syndrome (MetS),Giannopoulos et al. retrospectively analyzed the cerebral
vasomotor reactivity in subjects aged 59.19 ± 15. They
found an independent association of MetS with reduced
cerebrovascular reactivity, even after adjusting for age,
gender, race, cardiac disease, current statin therapy, and
small vessel disease [24]. Another study evaluated the
association of the components of the MetS separately
and in combination in 15 volunteers 59 ± 15 years old
without evidence of cerebrovascular disease by mag-
netic resonance. They found a non-significantly increased
cerebrovascular reserve calculated after administration of
acetazolamide, which was not associated with brain in-
creased oxygen extraction fraction [25].
Taking into consideration the relationship that obesity
has with cardiovascular risk factors, it is relevant to
know the effect of obesity, in absence of established car-
diovascular risk factors (age older than 60 years, hyperten-
sion, diabetes, smoking) on the intracranial hemodynamics
(PI, RI, and BHI) in comparison with subjects without
obesity, to determine if obesity is independently associated
with asymptomatic cerebrovascular dysfunction. Secondary
objectives are to determine the association of incipient
metabolic disorders (insulin resistance, glucose intolerance,
dyslipidemia) and high neck circumference with the vaso-
motor reactivity.
Research design and methods
We performed an observational, crossectional, case
control and prolective study. We included 85 con-
secutive subjects with obesity Class II and III accord-
ing to the World Health Organization (WHO) criteria
who attended the Obesity and Eating Disorders Clinic at
the Instituto Nacional de Ciencias Médicas y Nutrición
“Salvador Zubirán” in Mexico City, and 85 subjects with-
out obesity matched by age and gender who signed in-
formed consent. The study was approved by the institution
Ethics Committee of the Instituto Nacional de Ciencias
Médicas y Nutrición. Inclusion criteria were age 18 to
59 years. Exclusion criteria were recent bariatric sur-
gery (less than two years), weight loss ≥10% of body
weight in the last six months, known vascular disease
(coronary artery disease, CAD, arrhythmias, congest-
ive heart or kidney failure, cerebrovascular disease, periph-
eral vascular disease, and carotid stenosis >50%); chronic
obstructive pulmonary disease; acute infections; type 2 dia-
betes mellitus; hypertension; smoking; and inflammatory or
autoimmune diseases with vascular effects (arteritis, sys-
temic lupus erithematosus, rheumatoid arthritis).
The study protocol included measurement of weight,
height, BMI, abdominal circumference, and neck circum-
ference. Height was measured without shoes using a wall-
mounted stadiometer and weight was recorded on a
digital scale in a hospital gown. Clinical and metabolic var-
iables included blood pressure, fasting glucose, insulin and
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ance was defined as a 2 hour glucose ≥ 140 mg/dL with a
75 g glucose tolerance test [26]. HOMA-IR and Matsuda
indexes were calculated to assess insulin resistance in
all subjects [27,28]. Abdominal obesity was determined
by the presence of waist circumference >90 cm in men
and >80 cm in women, according to the International
Diabetes Federation (IDF) [29]. MetS was defined by
the presence of three or more of the following: waist cir-
cumference >90 cm in men and >80 cm in women, tri-
glycerides ≥ 150 mg/dl; HDL cholesterol < 40 mg/dl in
men and < 50 mg/dl in women; systolic blood pressure ≥
135 mm Hg or diastolic blood pressure ≥ 85 mm Hg; and
a fasting glucose ≥ 100 mg/dl, according to the worldwide
harmonizing definition of MetS of the International
Diabetes Federation (IDF), National Heart, Lung, and
Blood Institute (NHLBI), American Heart Association
(AHA), World Heart Federation (WHF), International
Atherosclerosis Society (IAS), and International Association
for the Study of Obesity (IASO) [30]. The Epworth Sleep
Scale and the Sleep Apnea Clinical Scale were applied to
every subject. Subjects with an ESS score ≥10 or a SACS
score ≥15 were considered with risk for OSA.
TCD were performed using a Pioneer TC ultrasound
4040 (Nicolet Biomedical Inc.) Resting velocities in the
mean cerebral arteries (MCA) were measured and after
ruling out vascular stenosis, cerebrovascular reactivity
was determined through the apnea test: During a 30-
second apnea, the BFV of the MCA are determined
through the temporal or ocular window. Systolic and dia-
stolic values 10 seconds after the apnea phase are regis-
tered. For each patient, the pulsatility (PI), resistance (RI)
and breath holding indexes (BHI) were calculated, the last
for the determination of the cerebrovascular reactivity
with the following formulas:
PI = PSV – EDV/MV.
RI = PSV – EDV/PSV.
BHI = 100 × [(apneaMV – restingMV/(restingMV × apneaT)]
[100] =% cm/seg19.
Where: PSV, peak systolic velocity; EDV, end-diastolic
velocity; MV, mean velocity (equal to PSV – EDV/3 + EDV);
T, time.
Statistical analysis
The analysis was made with a STATA Data Analysis and
Statistical Software Package version 11.1. Sample size
was calculated to detect a significant difference in me-
dian BHI between the comparison groups, with a power
of 90% to detect a difference of 15%, which gives 83
cases in every group. Results are presented as means ±
SEM when normally distributed and median (range)
when not. Baseline comparisons of continuous and cat-
egorical variables in subjects with and without obesity
were done by unpaired Student t test and chi2 test whendata were normally distributed, or Mann Whitney U test
and Fisher’s exact test for non-parametric, respectively.
A simple linear regression analysis was made between
the cerebrovascular reactivity and the independent vari-
ables (BMI, weight, abdominal circumference, neck cir-
cumference, glucose, insulin, insulin resistance indexes,
blood lipids, and scores in the ESS and SACS); those
with a linear association were included in a stepped mul-
tivariable linear regression to adjust for possible con-
founders associated with the cerebrovascular reactivity.
The BHI values were logarithmically transformed before
applying a linear regression. A logistic regression was
performed to identify factors associated with decreased
cerebrovascular reactivity. Decreased BHI was consid-
ered as the cut-off value below the 10th percentile of the
population without obesity. P values <0.05 were consid-
ered statistically significant.
Results
170 subjects were included in the study, 85 with obesity
and 85 subjects without obesity. The anthropometric
and metabolic variables within each group are shown in
Table 1. There was a predominance of women in the
sample (80%) given to the increased participation of
women in obesity programs. There were significant dif-
ferences in the metabolic variables between comparison
groups, with higher levels of glucose, insulin, and triglyc-
erides, higher values of HOMA-IR, and lower HDL
levels and Matsuda Index values in subjects with obesity
in comparison with subjects without obesity. There was
increased prevalence of metabolic syndrome and risk for
OSA according to questionnaires in the obese subjects
group as well.
There were no significant differences in the resting mean
velocity (MV) in the median cerebral arteries (MCA) in
subjects with obesity in comparison to subjects without
obesity, respectively. The cerebrovascular reactivity was
significantly lower in the group of subjects with obesity in
comparison with subjects without obesity. There were no
significant differences in the RI or in the PI in subjects
without obesity versus subjects without obesity. The same
results were found when analyzing according to abdominal
obesity (Table 2).
The variables with a significant negative linear associ-
ation with the cerebrovascular reactivity in a simple linear
regression were weight, BMI, waist, neck circumference,
and HOMA-IR. The Matsuda Index had a positive linear
association with it (Table 3). A multiple linear regression
was performed with the cerebrovascular reactivity as the
dependent variable and obesity as exposure factor. After
adjusting for Matsuda Index, neck circumference, and
waist circumference, there was an independent correlation
between the cerebrovascular reactivity and obesity accord-
ing to BMI, with an r2 of 0.1 (Table 4). When considering
Table 1 Characteristics of subjects with and without obesity
Non-obese Obese P-valuea
(n = 85) (n = 85)
Age, years 36 (26–44) 37 (27–44) 0.97a
Female, n (%) 68 (80) 68 (80) 1.00b
Anthropometric variables:
Weight, kg 58.6 (54–62.8) 107.4 (95.6-123.2) <0.001a
Height, m 160 (156–168) 161 (154–167) 0.82a
BMI, kg/m2 22.9 (21.3-24.7) 41.2 (38.5-45) <0.001a
Waist circumference, cm 76 (71–81.2) 117 (108.5-128) <0.001a
Neck circumference, cm 31 (29–33) 40 (37.8-42) <0.001a
Abdominal obesity, n (%) 15 (17) 84 (100) <0.001b
Metabolic variables:
Fasting glucose, mg/dL 86 (80–91) 90 (83–97) 0.002a
Fasting insulin, mg/dL 7.3 (5.8-9.8) 19 (12.9-26.5) <0.001a
HOMA-IR 1.6 (1.1-2.2) 4.4 (2.9-6) <0.001a
Matsuda index 3.9 (2.2-6.3) 7.8 (5.2-11.1) <0.001a
Glucose intolerance, n (%) 1 (1) 25 (29) <0.001b
Triglycerides, mg/dL 95 (73–131) 138 (102–188.5) <0.001a
Cholesterol, mg/dL 181 (164–203) 173.8 (152.8-201.5) 0.084a
HDL, mg/dL 53 (44–62) 42 (35–50) <0.001a
LDL, mg/dL 109 (89.5-122) 101.4 (82.4-121.1) 0.23a
Metabolic syndrome, n (%) 2 (2) 33 (38) <0.001b
OSA risk:
SACS, n (%) 0 4 (4) 0.121b
Epworth, n (%) 7 (8) 18 (21) 0.017b
Data shown as n (%) or median (Inter Quartile Range). aMann-Whitney U test; b, x2, or Fisher exact test as appropriate. BMI, Body Mass Index (weight in kilograms/
height in meters squared); HOMA-IR, Homeostasis Model Assessment- Insulin Resistance; LDL, Low Density Lipoprotein Cholesterol; HDL, High Density Lipoprotein
Cholesterol; OSA, Obstructive Sleep Apnea; SACS, Sleep Apnea Clinical Scale.
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below the 10th percentile of the BHI in subjects without
obesity (0.708), obesity according to BMI was an inde-
pendent risk factor for diminished cerebrovascular reactiv-
ity when adjusting for neck circumference and glucose
intolerance (Table 5).
Discussion
The present study found a significantly reduced cerebro-
vascular reactivity in young adults with obesity and in-
cipient metabolic disorders, which after adjustment for
insulin resistance, glucose intolerance, waist circumfer-
ence, and neck circumference showed and independent
association with elevated BMI.
Several studies have found a poor prediction of cardio-
vascular outcomes when categorizing people according
to BMI [14], so other anthropomethric measures have
been evaluated for disease prediction. A significant asso-
ciation between neck circumference with several cardio-
vascular risk factors has been demonstrated [31], inrelation with the respiratory obstruction that an elevated
neck circumference produces [32]. The fact that the lon-
gitudinal associations between neck and waist circumfer-
ence with the cerebrovascular reactivity were lost when
including BMI and insulin resistance, suggests that al-
though related with hemodynamic affection, an elevated
BMI have additional effects on the vasomotor reactivity
than the respiratory and metabolic impact that result
from the range of neck and waist circumference of the
participants.
Inclusion of subjects with moderate and severe obesity
confers a risk to include patients with OSA, but exclud-
ing patients with hypertension greatly reduces the risk of
OSA, since hypertension is one of the most often related
conditions [33], and one of the mechanisms by which OSA
promotes cardiovascular diseases, in addition to inflamma-
tory status, smooth muscle cell activation, endothelial dys-
function, and increased markers of atherosclerosis [34].
Besides OSA, obesity can affect respiratory physiology in
many other ways, including altered work of breathing,
Table 2 Doppler velocities and indexes in subjects with and without obesity according to BMI and according to
waist circumference
Artery Velocity/index Non obese (n = 79) Obese (n = 72) P
RMCA Resting MV, cm/s 59.3 (53.7-66) 60 (52.3-66) 0.73a
PI 0.89 (0.81-1) 0.90 (0.81-1.03) 0.70a
RI 0.56 (0.52-0.6) 0.56 (0.53-0.6) 0.68a
BHI 1.27 (0.94-1.58) 0.83 (0.56-1.21) <0.001a
Decreased BHI, n (%) 13 (16) 26 (36) <0.001b
Non obese (n = 79) Obese (n = 73)
LMCA Resting MV, cm/s 59 (55–66.3) 58 (51–66) 0.35a
PI 0.89 (0.8-1) 0.92 (0.79-1) 0.50a
RI 0.56 (0.52-0.6) 0.57 (0.52-0.6) 0.50a
BHI 1.14 (0.92-1.48) 0.89 (0.69-1.11) <0.001a
Decreased BHI, n (%) 8 (10) 21 (28) <0.001b
No abdominal obesity (n = 68) Abdominal obesity (n = 91)
RMCA Resting MV, cm/s 60 (53.8-66.3) 60.5 (53–66) 0.58a
PI 0.89 (0.8-1) 0.88 (0.82-1) 0.97a
RI 0.56 (0.52-0.6) 0.56 (0.53-0.6) 0.97a
BHI 1.26 (0.94-1.54) 0.92 (0.64-1.31) <0.001a
Decreased BHI, n (%) 12 (15) 26 (36) <0.001b
No abdominal obesity (n = 64) Abdominal obesity (n = 86)
LMCA Resting MV, cm/s 58.8 (54.8-67) 58 (50.7-65.7) 0.58a
PI 0.9 (0.83-0.98) 0.91 (0.78-1) 0.58a
RI 0.56 (0.53-0.6) 0.57 (0.52-0.6) 0.6a
BHI 1.14 (0.93-1.5) 0.94 (0.74-1.18) <0.001a
Decreased BHI, n (%) 6 (7) 23 (31) <0.001b
Data shown as n (%) or median (Inter Quartile Range). aMann-Whitney U test; b, x2, or Fisher exact test as appropriate. RMCA, Right Middle Cerebral Artery; LMCA,
Left Mean Cerebral Artery; MV, Mean Velocity; PI, Pulsatility Index; RI, Resistance Index; BHI, Breath Holding Index.
Table 3 Simple linear regression of variables associated
with the cerebrovascular reactivity
r2 β Sβ t p
Weight 0.06 −0.002 0.001 −3.07 0.003
BMI 0.06 −0.005 0.002 −3.19 0.002
Waist circumference 0.07 −0.002 0.001 −3.39 0.001
Neck circumference 0.05 −0.008 0.003 −2.85 0.005
Fasting glucose 0.02 −0.003 0.002 −1.94 0.05
Fasting insulin 0.03 −0.002 0.001 −2.03 0.04
HOMA-IR 0.03 −0.009 0.005 −1.98 0.05
Matsuda index 0.03 0.007 0.003 2.05 0.04
Glucose intolerance 0.03 −0.093 0.045 −2.08 0.04
Triglycerides 0.02 −0.000 0.000 −1.51 0.13
HDL 0.01 0.001 0.001 1.14 0.26
Somnolence (Epworth) 0.01 −0.062 0.047 −1.3 0.2
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bility to alter vascular function. Excluding subjects with
diabetes also is important for the study of incipient
changes in the cerebrovascular function, since it is one of
the main conditions that accelerate vascular damage [36].
Nevertheless, in the examination of the cerebrovascular
reactivity in subjects with incipient metabolic distur-
bances, insulin resistance did not show to have an inde-
pendent association with it. The fact that we found a
linear association between different metabolic and an-
thropometric variables with the cerebrovascular reactivity,
but with models reporting low coefficients of correlationTable 4 Multiple linear regression of variables associated
with the cerebrovascular reactivity
Variables β Sβ t P CI 95%
Obesity −0.154 0.07 −2.19 0.03 −0.29 −0.015
Matsuda index −0.002 0.003 −0.74 0.46 −0.007 0.003
Neck circumference 0.001 0.005 0.21 0.83 −0.01 0.012
Waist circumference 0.001 0.001 0.35 0.72 −0.002 0.004
Table 5 Logistic regression of variables associated with
decreased cerebrovascular reactivity
Variables OR SE P CI 95%
Obesity 4.98 3.61 0.03 1.2 20.66
Neck circumference 0.97 0.06 0.63 0.86 1.09
Glucose intolerance 0.81 0.46 0.72 0.27 2.5
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ent mechanisms that can influence the cerebrovascu-
lar hemodynamics.
Some studies have explored the development of vascu-
lar disorders in association with chronic diseases. One
study evaluated the cerebrovascular reactivity in associ-
ation with cognitive performance and brain volumes in
subjects with type 2 diabetes mellitus 56–80 years old at
baseline and after four years. Subjects with diabetes had
worse cognitive performance and smaller brain volumes
in comparison with the control group, but these charac-
teristics did not correlate with the cerebrovascular reactiv-
ity, nor with the progressive decline of brain volume in
the follow-up [37]. Several reports have shown the associ-
ation between MetS with ischemic stroke, white matter
alteration, and altered brain metabolism in nonelderly
adults; and with cognitive dysfunction, in particular in ex-
ecutive function in adolescents [38]. As for obesity alone,
one report failed to find statistically significant cognitive
impairment associated with obesity [39]. The assessment
of the carotid circulation through Doppler ultrasound
in subjects free of cardiovascular disease, with and with-
out metabolic syndrome (MS) showed that incidence of
cardiovascular events (myocardial infarction, transient
ischemic attack, abdominal aortic aneurysm, and thrombo-
endo-arterectomy) in a 20-year follow-up was higher
among subjects aged 62 ± 12 years old with metabolic syn-
drome (MetS), and the incidence increased whenever there
was presence of preclinical carotid atherosclerosis [40].
The reduction of the cerebrovascular reactivity trans-
lates in an altered capacity for vasodilation of the cere-
bral arteries, which has been associated with the future
development of cerebrovascular disease [41]. In this study,
the assessment of subjects without established cardiovas-
cular risk factors did not show an advanced disorder in
the cerebrovascular hemodynamics, since the PI, which
translates distal vascular resistance and is altered in clin-
ical vascular damage [42], was not different in subjects
with obesity in comparison with subjects without obesity.
The breath holding index is an incipient vascular dysfunc-
tion marker, which was negatively related with factors
accompanying an elevated BMI. Lack of measurement of
all the mechanical and inflammatory mechanisms coexist-
ent with obesity with a vascular repercussion represents a
limitation to explain the altered cerebrovascular reactivity
that we found.This study highlights the importance of understanding
the implicated mechanisms that an elevated BMI has on
the cerebrovascular hemodynamics in young adults, in
absence of other established risk factors for stroke.
Additional studies are needed to discover the different
processes that determine a clinical event in the pres-
ence of this alteration of the cerebrovascular reactivity,
and to examine the interactions of multiple phenomena
contributing with the development of cerebrovascular
disease.
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